All In Biotech

Drug Trial Radar · NCT07233655

A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis

A Randomized, Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of SHR-3045 Injection in Patients With Moderate to Severe Active Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Actual

Start

Jan 19, 2026

Primary completion

Apr 21, 2026

Study completion Jul 2026

Sponsor

Sponsor type
Industry
First posted
Nov 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is ongoing to explore the efficacy and safety of different strengths of SHR-3045 injection in moderate to severe active rheumatoid arthritis.

Conditions

  • Moderate to Severe Active Rheumatoid Arthritis

Interventions

  • SHR-3045 InjectionDrug

    SHR-3045 injection.

  • SHR-3045 Injection PlaceboDrug

    SHR-3045 injection placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of subjects who achieved a 20% improvement in the American College of Rheumatology Rheumatoid Arthritis (RA) disease activity assessment core set.Time frame: After 14 weeks of treatment.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People 's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.